Copper bis(diphosphine) complexes: Radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET

European Journal of Nuclear Medicine

Volumn 27, Issue 6, 2000, Pages 638-646

  Lewis, Jason S ^a,c   Dearling, Jason L J ^a   Sosabowski, Jane K ^b   Zweit, Jamal ^b   Carnochan, Paul ^b   Kelland, Lloyd R ^b   Coley, Helen M ^b   Blower, Philip J ^a,d  

^a UNIVERSITY OF KENT   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

Copper 64; Diphosphines; Multi drug resistance; Positron emission tomography; Tumour

Indexed keywords

COPPER; CYCLOSPORIN A; DOXORUBICIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ARTICLE; CHEMICAL STRUCTURE; DIAGNOSTIC IMAGING; HALF LIFE TIME; HUMAN; HUMAN CELL; IMAGE ANALYSIS; ISOTOPE LABELING; MULTIDRUG RESISTANCE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; RAT;

ANIMALS; CHO CELLS; COPPER RADIOISOTOPES; CRICETINAE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PHOSPHINES; RADIOPHARMACEUTICALS; RATS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR CELLS, CULTURED;

EID: 0034123696     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050557     Document Type: Article

References (33)

1. 1. Hill BT. Drug resistance: an overview of the current state of the art. Int J Oncol 1996; 9: 197-203.
2. 2. Clynes M. Multiple drug resistance in cancer. Dordrecht: Kluwer Academic Publishers, 1998.
3. 3. Bae KT, Piwnica-Worms D. Pharmacokinetic modeling of multi-drug resistance P-glycoprotein transport of gamma-emitting substances. Q J Nucl Med 1997; 41: 101-110.
4. 4. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434-442.
5. 5. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deley RG. Overexpression of a transporter gene in a multi-drug resistant human cancer cell line. Science 1992; 258: 1650-1654.
6. 6. Kool M, de Haas M, Scheffer G, Scheper R, Van Eijk M, Juijn J, Baas F, Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance associated protein gene (MRP1) in human cancer cell lines. Cancer Res 1997; 57: 3537-3547.
7. 7. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994; 35: 510-515.
8. 8. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug resistant breast tumor cells. J Nucl Med 1996; 37: 1578-1582.
9. 9. Ballinger JR, Muzzammil T, Moore MJ. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors. J Nucl Med 1997; 38: 1915-1919.
10. 10. Crankshaw CL, Marmion M, Luker GD, Rao V, Dahlheimer J, Burleigh BD, Webb E, Deutsch KF, Piwnica-Worms D. Novel technetium-(III)-Q complexes for functional imaging of multi-drug resistance (MDE1) P-glycoprotein. J Nucl Med 1998; 39: 77-86.
11. 11. Duran Cordobes M, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdjian J-C, Prevost G, Caglar M, Moretti J-L. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996; 37: 286-289.
12. 12. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 1994; 21: 357-362.
13. 13. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium in cultured mouse fibroblasts. J Nucl Med 1990; 31: 1646-1653.
14. 14. De Moerloose B, van de Wiele C, Dhooge C, Philippé J, Speleman F, Benoit Y, Laureys G, Dierckx RA. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein. Eur J Nucl Med 1999; 26: 396-403.
15. 15. Luker GD, Fracasso PM, Dobkin J, Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med 1997; 38: 369-372.
16. 16. Cwikla JB, Buscombe JR, Barlow RV, Kelleher SM, Parbhoo SP, Crow J, Deery A, Jones AL, Hilson AJW. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer. Eur J Nucl Med 1997; 24: 1175-1178.
17. 99mTc-Q12 into human breast cancer cell lines. Eur J Nucl Med 1996; 23: 1361-1366.
18. 99mTc-sestamibi in vitro. Anticancer Res 1997; 17: 1833-1840.
19. 19. Sharma V, Polyakov V, Beatty A, Wey S-P, Bass L, Dahlheimer J, Crankshaw CL, Green MA, Welch MJ, Piwnica-Worms D. Gallium(III) Schiff-base complexes as potential PET agents for evaluation of multidrug resistance (MDR1) P-glycoprotein transport activity. J Labelled Cpd Radiopharm 1999; 42 Suppl 1: S273-S275.
20. 20. Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999; 26: 283-293.
21. 21. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radio-pharmaceuticals in nuclear medicine. Nucl Med Biol 1996; 23: 957-980.
22. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24: 35-43.
23. 23. Zweit J, Goodall R, Cox M, Babich JW, Potter GA, Sharma HL, Ott RJ. Development of a high-performance zinc-62/copper-62 radionuclide generator for positron emission tomography. Eur J Nucl Med 1992; 19: 418-425.
24. 24. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, Lewis JS, Cutler CS, Anderson CJ, Welch MJ. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 1999; 26: 351-358.
25. 25. Berners-Price SJ, Sadler PJ. Phosphines and metal phosphine complexes: relationship of chemistry to anticancer and other biological activity. Structure and Bonding 1988; 70: 27-102.
26. 26. Berners-Price SJ, Johnson RK, Giovenella AJ, Faucette LF, Mirabelli CK, Sadler PJ. Antimicrobial and anticancer activity of tetrahedral, chelated, diphosphine silver(I) complexes: comparison with copper and gold. J Inorg Biochem 1988; 33: 285-295.
27. 2]Cl and analogous complexes (dppe = 1,2-bis(diphenylphosphino)ethane). Polyhedron 1998; 17: 513-517.
28. 64Ni targets for positron emission tomography. Appl Radiat Isot 1991; 42: 193-197.
29. 4-methylthiose-micarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med 1994; 21: 336-341.
30. 30. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 1989; 59: 527-534.
31. 31. Sharp SY, Rowlands MG, Jarman M, Kelland LR. Effects of a new antioestrogen, idoxefine, on cisplatin-and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer 1994; 70: 409-414.
32. 32. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard Jones K. Biricodar (VX-710; Incel ™): an efficient chemosensitiser in neuroblastoma. Br J Cancer 1999; 80: 1190-1196.
33. 33. Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, Chiu KW, Edwards B, Gill HK, McPartlin M, Nagle KR, Latham IA, Pickett RD, Storey AE, Webbon PM. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993; 34: 222-227.